  
 **2nd Annual Henry Ford Cancer Thoracic Multidisciplinary Symposium (2024) | 11/22/2024 7:00 AM The Henry Hotel**

Thoracic symposium that provides the latest information to the management and diagnosis of lung cancer in a multidisciplinary format. Update clinical teams on the importance of biomarker testing in NSCLC. Update the teams on surgical management of NSCLC. Update the clinical teams on the role of radiation therapy in the management of NSCLC. Update the clinical teams on new advances and medications available for the treatment of NSCLC. Lastly, they will have a chance to attend a talk by a patient advocate on the patients' perspective on lung cancer treatment and research.

**Program Goal**

1 To be up-to-date on the recent advances in the management of NSCLC.

2 To be able to apply these advances in the treatment of their patients and in a multidisciplinary format.

3 To understand the role of each specialty involved in the management of this disease.

4 To understand the role of multidisciplinary teams in the management of NSCLC.

5 To understand the importance of biomarker testing in NSCLC.

6 To understand patients' perspectives on treatment and research of NSCLC.

7 To understand the role of lung cancer screening in the early detection of NSCLC.

**Target Audience** Hematology / Oncology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Andrew Popoff, MD | Faculty | Consulting Fee-Astrazeneca - 03/25/2024 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 02/20/2024 |
| Shirish Gadgeel, MD | Course Director, Faculty | Consulting Fee-Takeda, Janssen, Daichii, Lilly, Novartis, Merck, Arcus, Esai, Gilead, GSK (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astrazeneca|Advisor-AbbVie (Relationship has ended)|Advisor-Amgen (Relationship has ended)|Advisor-Bayer (Relationship has ended)|Advisor-Genentech (Relationship has ended)|Advisor-Pfizer (Relationship has ended)|Advisor-BMS (Relationship has ended) - 08/27/2024 |
| Avi Cohen, MD | Faculty | Consulting Fee-PulmonX - 10/31/2024 |
| Fawzi Abu Rous, MD | Co-Director, Faculty | Honoraria-MJH life sciences (Relationship has ended)|Honoraria-IntrinsiQ Specialty Solutions (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astrazeneca (Relationship has ended)|Advisor-Genentech|Grant or research support-ASCO YIA - 02/08/2024 |
| Denise Brooks, MBA | CME Specialist | Nothing to disclose - 06/26/2024 |
| Tressa Cuschieri, BBA | Activity Coordinator | Nothing to disclose - 01/11/2024 |
| Khaled Adil, MD | Faculty | Nothing to disclose - 08/23/2024 |
| Radhika Gutta, DO-Fellow | Faculty | Nothing to disclose - 08/26/2024 |
| Terri Conneran, BS, Oncology Survivor KRAS Lung | Faculty | Advisor-BMS|Advisor-Genentech|Consulting Fee-Pfizer|Consulting Fee-Astrazeneca (Relationship has ended)|Consulting Fee-Amgen|Honoraria-Merck (Relationship has ended)|Consulting Fee-Loxo, Lilly (Relationship has ended)|Honoraria-Boehringer Ingelheim (Relationship has ended)|Honoraria-Frontier Medicine (Relationship has ended)|Consulting Fee-Revolution Medicines|Honoraria-Qiagen (Relationship has ended)|Advisor-Astellas (Relationship has ended)|Consulting Fee-Exact Sciences (Relationship has ended)|Advisor-Fortrea (Relationship has ended)|Advisor-Guardant (Relationship has ended)|Advisor-Astrazeneca (Relationship has ended) - 08/26/2024 |
| Nasser Hanna, MD | Faculty | Grant or research support-BMS|Grant or research support-Merck|Grant or research support-Genentech - 08/20/2024 |
| Yasir Elamin, MD | Faculty | Consulting Fee-BMS (Relationship has ended)|Consulting Fee-Taiho Pharmaceutical|Consulting Fee-Astrazeneca (Relationship has ended)|Consulting Fee-Takeda - 08/20/2024 |
| Mark Awad, MD, PhD | Faculty | Nothing to disclose - 09/03/2024 |
| Kathryn C Arbour, MD | Faculty | Advisor-Amgen (Relationship has ended)|Advisor-Revolution Medicines (Relationship has ended)|Advisor-Astrazeneca (Relationship has ended)|Advisor-Novartis (Relationship has ended)|Advisor-Lilly (Relationship has ended)|Advisor-Merck (Relationship has ended)|Advisor-BMS (Relationship has ended) - 09/04/2024 |
| Angel Qin, MD | Faculty | Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-Pfizer (Relationship has ended)|Consulting Fee-Janssen|Honoraria-OncLive (Relationship has ended)|Consulting Fee-Regeneron (Relationship has ended)|Consulting Fee-Summit Therapeutics (Relationship has ended)|Consulting Fee-Strata Oncology (Relationship has ended) - 10/11/2024 |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT:** Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 6.00 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated prior to the commencement of the activity.

**ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator Tressa Cuschieri at TCUSCHI1@hfhs.org If you have questions, please email Tressa Cuschieri at TCUSCHI1@hfhs.org. Please allow a minimum of 3 days to process this request.